Ovarian Cancer Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Ovarian Cancer Information Center has current, evidence-based information for you. Get the facts about ovarian cancer prevention, early detection, treatment, and survivorship, and stay up to date with ongoing ovarian cancer research that could impact your treatment decisions through our daily cancer news.
You are not alone—The CancerConnect Ovarian Cancer Community is the leading Social Media Application for Ovarian Cancer patients and caregivers seeking information, inspiration, and support in the wake of a cancer diagnosis. With over 50,000 members the network offers patients and caregivers a thriving community to support the many ongoing needs from diagnosis to survivorship. Login or register here.
Gradalis, Inc. a clinical stage cellular immunotherapy company, developing Vigil®... FDA Approves Avastin® (Bevacizumab) Plus Chemotherapy for Treatment of Advanced Ovarian Cancer
Genentech announced that the U.S. Food and Drug Administration (FDA) has approved... Lynne Cohen Foundation: What an Incredible Year!
WHAT AN INCREDIBLE YEAR! PREVENTIVE CARE CLINICS Our four Lynne Cohen Preventive...
Ovarian cancer is a critical women’s health issue; According to the American Cancer... What Every Woman Should Know about Gynecologic Cancer
By Barbara A. Goff, MD, President, Society of Gynecologic Oncology and Foundation... 10 Things Every Woman Should Know About Ovarian Cancer
Critical tips about screening and what to expect during treatment.
Ovarian Cancer Management
Ovarian cancer is a critical women’s health issue; According to the American Cancer... Q&A: The Next Step: Thriving through Survivorship
Ritu Salani, MD Gynecologic Oncologist The Ohio State University Comprehensive Cancer... Ovarian Survivor Profile
Brenda Maxwell, 59 Fishkill, New York I was busy as a wife, mom, and grandmother...
Ovarian Cancer Clinical Trials
GOG0213 – AA Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
GOG-0218 – Phase III Trial of Carboplatin and Paclitaxel Plus Placebo versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab followed by Placebo, versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women with Newly Diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian and Primary Peritoneal Cancer
INST0708C – Biological Study: Assessment of Genetic Alterations in the Signaling Network as Prognostic Markers in Ovarian Cancer